- Novo Nordisk’s actions are climbing thanks to the latest results of weight loss tests Financial time
- Novo Nordisk’s stock appears on phase 1 data of the new AMYCRETINE MAYAGERANTICAL DIGINE Yahoo Finance
- Novo Nordisk’s shares jump by 14 % thanks to the results of a preliminary trial on a mild drug CNBC
- Novo Nordisk shares the results of a new obesity medication The Wall Street Journal
- The actions of the manufacturer Ozempic increase. A trial of a new Novo Nordisk medication is promising. Market surveillance
Novo Nordisk’s actions leaps thanks to the latest results of a weight loss trial – Financial Times
